Can gefitinib cure lung cancer?
For non-small cell lung cancer (NSCLC) harboring activating EGFR mutations, tyrosine kinase inhibitors (TKIs) such as gefitinib are remarkably effective [1], and no cured case of advanced NSCLC has been reported yet. Here, we now report the first case of EGFR-mutated lung adenocarcinoma cured with gefitinib.
What cancers does gefitinib treat?
Gefitinib is a treatment for non small cell lung cancer (NSCLC) that has spread into the surrounding tissues (locally advanced) or to other parts of the body. Gefitinib is also used in clinical trials for other cancer types.
What is the mechanism of gefitinib?
Mechanism of Action Gefitinib is an EGFR tyrosine kinase inhibitor. It works by binding to the intracellular enzyme (tyrosine kinase) of the EGFR to directly block signals turned on by triggers outside or inside the cell.
Is gefitinib a growth factor receptor inhibitor?
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.
Is Iressa chemotherapy?
Summary: Gefitinib, also known as Iressa, the once-promising targeted therapy for the treatment of nonsmall cell lung cancer, has proven as effective as chemotherapy as a second-line therapy for the disease with far fewer side effects, according to an international Phase III clinical trial.
How long can you take gefitinib?
The chemotherapy used is a relatively standard regimen of infusions every 3 weeks for four cycles — or 12 weeks of therapy — whereas gefitinib is a daily pill they take for 2 years.
Why was gefitinib withdrawn?
On August 26, 2010, FDA requested that AstraZeneca voluntarily withdraw IRESSA (gefitinib) Tablets from the market, because the postmarketing studies required as a condition of approval under subpart H failed to verify and confirm clinical benefit.
What are the side effects of gefitinib?
Side Effects
- Abdominal or stomach pain or tenderness.
- clay colored stools.
- decreased appetite.
- diarrhea, severe.
- itching or skin rash.
- nausea and vomiting.
- swelling of the feet or lower legs.
- yellow eyes or skin.
Is gefitinib a TKI?
Background. Gefitinib was the first epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) approved for the treatment of advanced non-small cell lung cancer (NSCLC).